Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study

References

• Global Initiative for Chronic Obstructive Lung Disease Pocket Guide to Copd Diagnosis, Management, and Prevention a Guide for Health Care Professionals; 2017.
   Google Scholar
• RabeKF, HurdS, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:532–555. doi:10.1164/rccm.200703-456SO17507545
   PubMed Web of Science ®Google Scholar
• BloomCI, ElkinS, QuintJ. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi:10.2147/COPD.S19008630774325
   PubMed Web of Science ®Google Scholar
• DrivenesE, OstremA, MelbyeH. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15:42. doi:10.1186/1471-2296-15-4224597538
   PubMed Web of Science ®Google Scholar
• BarrechegurenM, MonteagudoM, FerrerJ, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47–53. doi:10.1016/j.rmed.2015.12.00426758585
   PubMed Web of Science ®Google Scholar
• Casas HerreraA, Montes de OcaM, MenezesA, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556. doi:10.2147/COPD29785104
   PubMed Web of Science ®Google Scholar
• TavakoliH, JohnsonKM, FitzGeraldJM, et al. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. Int J Chron Obstruct Pulmon Dis. 2019;14:2003–2013. doi:10.2147/COPD31564848
   PubMed Web of Science ®Google Scholar
• BrusselleG, PriceD, Gruffydd-JonesK, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S9169426527869
   PubMed Web of Science ®Google Scholar
• HoritaN, GotoA, ShibataY, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD) In: HoritaN, editor. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2017. doi:10.1002/14651858.CD012066.pub2
   Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• VogelmeierC, PaggiaroPL, DorcaJ, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a Phase 3 COPD study. Eur Respir J. 2016;48:1030–1039. doi:10.1183/13993003.00216-201627492833
   PubMed Web of Science ®Google Scholar
• CazzolaM, RoglianiP, CalzettaL, MateraMG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52:1801586. doi:10.1183/13993003.01586-201830309975
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy De-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198:329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• RossiA, van der MolenT, OlmoRD, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548–1556. doi:10.1183/09031936.0012681425359348
   PubMed Web of Science ®Google Scholar
• RossiA, GuerrieroM, CorradoA; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-7725005873
   PubMed Web of Science ®Google Scholar
• VogelmeierC, WorthH, BuhlR, et al. ‘Real-life’ inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S12561628203072
   PubMed Web of Science ®Google Scholar
• Primary Care respiratory Society. Stepping down inhaled corticosteroids in COPD. Available from: https://www.pcrs-uk.org/resource/stepping-down-inhaled-corticosteroids-copd. Accessed 108, 2019.
   Google Scholar
• HerrettE, GallagherAM, BhaskaranK, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827–836. doi:10.1093/ije/dyv09826050254
   PubMed Web of Science ®Google Scholar
• QuintJK, MullerovaH, DiSantostefanoRL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4:e005540–e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• RothnieKJ, MüllerováH, ThomasSL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin. Epidemiol. 2016;8:771–782. doi:10.2147/CLEP27920578
   PubMed Web of Science ®Google Scholar
• RothnieKJ, MüllerováH, HurstJR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11:e0151357. doi:10.1371/journal.pone.015135726959820
   PubMed Web of Science ®Google Scholar
• NissenF, MoralesDR, MullerovaH, et al. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 2017;7:e017474. doi:10.1136/bmjopen-2017-017474
   PubMed Web of Science ®Google Scholar
• SulkuJ, JansonC, MelhusH, et al. A cross-sectional study assessing appropriateness of inhaled corticosteroid treatment in primary and secondary care patients with COPD in Sweden. Int J COPD. 2019;14:2451–2460. doi:10.2147/COPD
   Google Scholar
• Román-RodríguezM, van BovenJFM, VargasF, et al. Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: a cross-sectional study in the Balearic Islands (Spain). Eur. J. Gen. Pract. 2016;22:232–239. doi:10.1080/13814788.2016.121201127597172
   PubMed Web of Science ®Google Scholar
• CrimC, CalverleyPMA, AndersonJA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 2009;34:641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• ErnstP, GonzalezAV, BrassardP, SuissaS. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162–166. doi:10.1164/rccm.200611-1630OC17400730
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, StockleyRA, SeemungalTAR, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139:505–512. doi:10.1378/chest.09-299220576732
   PubMed Web of Science ®Google Scholar
• BrodeSK, CampitelliMA, KwongJC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50:1700037. doi:10.1183/13993003.00037-201728931659
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• PriceD, HaughneyJ, SimsE, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy. 2011;4:37–47. doi:10.2147/JAA.S1770921698214
   PubMedGoogle Scholar
• TraversJ, MarshS, WilliamsM, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62:219–223. doi:10.1136/thx.2006.06683717105779
   PubMed Web of Science ®Google Scholar
• SulaimanI, CushenB, GreeneG, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–1343. doi:10.1164/rccm.201604-0733OC27409253
   PubMed Web of Science ®Google Scholar
• SulaimanI, SeheultJ, MacHaleE, et al. Irregular and ineffective: a quantitative observational study of the time and technique of inhaler use. J Allergy Clin Immunol Pract. 2016;4:900–909.e2. doi:10.1016/j.jaip.2016.07.00927587321
   PubMed Web of Science ®Google Scholar
• ThomasM, PriceD, ChrystynH, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1. doi:10.1186/1471-2466-9-119121204
   PubMedGoogle Scholar